Humana Inc.

The release of the 2027 CMS Advance Notice in early February 2026 has introduced a significant headwind for Humana Inc. (HUM), complicating its multi-year trajectory toward recovering individual Medicare Advantage (MA) margins to its 4-5% target. The proposed rate update, characterized by the industry as a "flat" environment, necessitates a more aggressive reliance on benefit redesign and operational efficiencies to offset reimbursement pressures.

1. CMS 2027 Advance Notice: The Reimbursement Reality

The 2027 Advance Notice proposed a net average year-over-year payment increase of only 0.09%. While CMS projects an expected average change in revenue of 2.54% when factoring in the "risk score trend" (coding practices and population changes), this remains significantly below the 4% to 6% increase anticipated by Wall Street analysts.

• Effective Growth Rate: The benchmark growth is estimated at 4.97%, driven by Original Medicare per capita costs.
• Risk Model Impact: Revisions and normalization are expected to create a -3.32% drag on payments.
• Source of Diagnoses: The exclusion of unlinked chart review records and audio-only encounters is projected to reduce payments by -1.53%.

For Humana, which is a "pure-play" MA insurer with over 80% of its revenue tied to Medicare, these rates are effectively a real-dollar cut when adjusted for medical inflation and rising utilization trends.

2. Impact on Margin Recovery Targets

Humana’s path to its 4-5% margin target is currently bifurcated by a severe "Star Ratings cliff" in 2026 and the flat 2027 rate environment.

• 2026 Margin Headwinds: Humana entered 2026 with a $3.5B net headwind due to a drop in Star Ratings, with only 25% of its members in 4-star plans or higher. Consequently, 2026 MA margins are expected to be slightly below breakeven.
• 2027 Recovery Trajectory: The 2027 rate proposal slows the "margin over membership" reset. Management had previously targeted a return to 3% margins by 2027 as a stepping stone to the 4-5% long-term goal. The current proposal makes the 3% interim target highly dependent on aggressive bid pricing and benefit cuts.
• Utilization Pressures: Continued high utilization in outpatient services and the rising cost of GLP-1 drugs (where covered) further compress the medical loss ratio (MLR), which stood at 90.4% for FY 2025.

3. Specific Benefit Design Changes for the 2027 Bid Cycle

To mitigate the 0.09% base rate update, Humana is implementing a "Right-Sizing" strategy for the 2027 bid cycle, shifting away from the "generosity" that drove its 1M member growth in 2026.

• Supplemental Benefit Rationalization: Humana is expected to scale back non-core supplemental benefits (e.g., dental, vision, and fitness allowances) in underperforming counties. The focus is shifting from "attraction" benefits to "retention" services.
• Market & Plan Exits: Following the exit from certain unprofitable markets in 2025 (shedding 500,000 members), Humana is conducting a granular county-by-county profitability analysis for 2027. Plans that cannot achieve a sustainable margin under the new risk-adjustment models will likely be terminated or consolidated.
• Part D Redesign Integration: Humana is redesigning its Part D offerings to align with the Inflation Reduction Act (IRA) changes taking full effect in 2027, including the $2,000 out-of-pocket cap and the shift in manufacturer discount obligations.
• Clinical Value-Based Offsets: Humana is leveraging its CenterWell segment to drive medical cost savings. By shifting more members into "payvider" models, Humana aims to capture the provider-side margin to offset the insurance-side reimbursement squeeze.

4. Operational & Administrative Levers

Beyond benefit design, Humana is accelerating its $2.5B value-creation program to find internal offsets:

• Administrative Efficiency: Reducing SG&A through tech-enabled backend automation to generate operating leverage.
• Risk Adjustment Accuracy: Enhancing clinical documentation to mitigate the -1.53% impact from the new "Source of Diagnoses" rules, focusing on documented face-to-face encounters over chart reviews.

Summary of Key Financial Metrics

To demonstrate that its quality-score recovery plan is on track to restore bonus payments for the 2027 plan year, Humana must execute a series of critical operational milestones in the current quarter (Q1 2026). Because the 2027 Star Ratings (released in October 2026) are primarily based on performance during the 2025 measurement year and member surveys conducted in early 2026, this quarter represents the final window to influence key experience metrics and finalize clinical data submissions.

1. CAHPS Survey Execution & Member Onboarding

The Consumer Assessment of Healthcare Providers and Systems (CAHPS) surveys, which carry a heavy weight in the Star Ratings formula, are fielded starting in March 2026.

• Proactive Outreach: Humana must demonstrate high "touchpoints" for the 1M+ new members gained during the 2026 Annual Election Period (AEP). Investors will look for evidence of successful "Welcome Calls" and health risk assessments (HRAs) completed within the first 90 days of enrollment.
• Pharmacy Transition Management: A major driver of member dissatisfaction is formulary friction. Milestones include the successful transition of members to new drug protocols without "late refill" spikes, which Humana previously noted it reduced by 30% to 50% in prior recovery phases.

2. HEDIS Data Finalization (2025 Measurement Year)

While the clinical care occurred in 2025, the administrative "closing" of these gaps occurs in Q1 2026.

• Gap Closure Validation: Humana must finalize the collection of medical records to prove clinical actions (e.g., colorectal screenings, diabetes eye exams) were taken. Management has targeted a 25% year-over-year increase in care gap closures.
• HOQ Submission: A technical but vital milestone is the completion of the Healthcare Organization Questionnaire (HOQ) by early February, which sets the stage for formal HEDIS and CAHPS data submission IDs.

3. Contract Diversification & Member Migration Results

Humana’s primary mitigation strategy for the $3.5B revenue headwind in 2026 is "contract diversification"—moving members from low-rated contracts into those that maintained 4-star or higher ratings.

• AEP Attribution Audit: In Q1, Humana must confirm the final distribution of its ~6.2M individual MA members. Investors are looking for proof that the percentage of members in 4-star+ plans for the 2027 payment year will be "meaningfully higher" than the 20% reported for 2026.
• Retention Metrics: Following the 2026 AEP, Humana needs to report a stabilization or improvement in its retention rate (which improved by 500 bps in 2025) to ensure the "quality mix" of the membership remains favorable.

4. Regulatory & Administrative Deadlines

• CTM Data Review (March 31): Humana must complete its review of the Complaints Tracking Module (CTM) data for 2025. Reducing member complaints is a direct lever for Star Ratings; any discrepancies must be challenged by this end-of-quarter deadline to protect the 2027 score.
• CenterWell Integration: Investors will monitor the "clinical pull-through" of members into Humana’s CenterWell primary care clinics. Achieving higher utilization of internal clinics in Q1 is a leading indicator of better HEDIS outcomes and lower medical loss ratios (MLR).

5. Financial Discipline & 2026 Guidance Stability

• MLR Management: After a difficult 2025 where the benefit ratio hovered near 90%, Humana must show in its Q1 results (typically released in late April) that it is successfully managing medical utilization.
• EPS Floor: Maintaining the FY 2026 Adjusted EPS guidance of "at least $9.00" is essential. Any downward revision in Q1 would signal that the "Stars recovery" is being overwhelmed by higher-than-expected medical costs or failed contract migration.

The recent volatility in Humana’s Medical Loss Ratio (MLR), which spiked to 93.1% in Q4 2025, has intensified the focus on CenterWell, the company’s healthcare services division. As Humana’s core insurance segment (HPS) grapples with a "perfect storm" of elevated outpatient utilization and regulatory headwinds, CenterWell is increasingly viewed not just as a growth engine, but as a structural hedge designed to capture and manage the very medical spend that is currently eroding insurance margins.

1. The Mechanics of the "Internal Hedge"

The strategic rationale for CenterWell lies in the Integrated Care Model. When medical utilization rises—driven by trends such as orthopedic surgeries or the high cost of GLP-1 drugs—it manifests as a liability for the insurance segment. However, under Humana’s value-based care (VBC) framework, CenterWell captures a portion of this spend as revenue.

• Utilization Capture: CenterWell’s primary care, pharmacy, and home health assets allow Humana to internalize medical spend. In 2025, CenterWell revenue grew to $22.5B, up from $19.9B in 2024.
• Cost Avoidance: Data indicates that Humana members treated at CenterWell facilities experience 11.6% fewer ER visits and 7.2% fewer hospital admissions compared to those in non-VBC settings. This efficiency directly mitigates the MLR pressure on the insurance side.
• Revenue Diversification: While the insurance segment reported a $796M loss in Q4 2025, CenterWell’s fee-based and clinical income provides a more stable, non-underwriting-based cash flow stream.

2. Evaluating the Valuation Premium

Investors typically apply a Sum-of-the-Parts (SOTP) valuation to Humana, assigning significantly higher multiples to CenterWell than to the core Medicare Advantage (MA) business.

• Multiple Arbitrage: Pure-play managed care organizations (MCOs) often trade at 8x–10x EBITDA, whereas healthcare services and VBC platforms can command 12x–18x EBITDA due to their capital-light (in pharmacy/home) or high-retention clinical models.
• Earnings Stability: CenterWell’s margins are less sensitive to the "Star Ratings cliff"—a $3.5B headwind facing Humana in 2026—because its revenue is derived from service delivery rather than government bonus pools.
• Growth Trajectory: CenterWell is expanding aggressively, with plans to add 20–30 new senior primary care centers in 2025, bringing its total to over 340 locations. This expansion supports a higher terminal value for the segment.

3. Risks and Limitations to the Hedge

While CenterWell acts as a buffer, it is not a perfect hedge against the systemic risks currently facing the MA industry.

• Capacity Constraints: CenterWell currently serves approximately 390,000 seniors, a fraction of Humana’s 6.3M individual MA members. The "hedge" only works for the portion of the membership that is geographically and clinically integrated into the CenterWell ecosystem.
• Regulatory Squeeze: While CenterWell is "payor-agnostic," it still relies heavily on the Medicare reimbursement environment. If CMS continues to propose near-flat rate increases (such as the 0.09% net increase proposed for 2027), the entire value chain—both payor and provider—faces margin compression.
• Capital Intensity: Unlike the insurance business, the Primary Care Organization (PCO) requires significant CapEx for clinic builds and "J-curve" losses during the ramp-up phase of new centers.

4. Institutional Outlook

For investors, the valuation premium of CenterWell is justified by its role in de-risking the underwriting cycle. As Humana resets its 2026 earnings guidance to "at least $9.00" per share (down from $17.14 in 2025), the "Services" segment represents the primary path to margin recovery. The long-term investment thesis depends on Humana's ability to shift more members into this integrated model to decouple earnings from the volatility of federal reimbursement and unpredictable utilization spikes.